JAMA Cardiology article presents Kaplan-Meier curves for time to all-cause mortality (ACM) and cardiovascular-related mortality (CVM) through month 54. Graphs compare continuous acoramidis to placebo, showing survival probability over time with stratified Cox regression analysis.

Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months.

#ACC26 @accintouch.bsky.social

ja.ma/4bGqr9d

This Black History Month, we honor our history by protecting our future. ATTR-CM is a rare but serious heart condition that often goes undiagnosed—especially in Black communities.
Learn the signs. Ask your doctor.
Visit AskAboutATTR.org to learn more.
#BlackHistoryMonth #ATTRCM #LiftEveryVoice

AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges This article explores key differences and diagnostic challenges between light-chain amyloidosis and ATTR-CM.

Accurate differentiation between light-chain (AL) amyloidosis and #ATTRCM is critical for effective patient management, as misclassification can delay life-saving therapies for #ALAmyloidosis or result in unnecessary interventions for ATTR-CM.

Learn more: https://bit.ly/4q8BrAH

Conduction Abnormalities Appear More Common Than Cardiomyopathy in Patients With TTR V30M Significant conduction abnormalities were more frequent than overt amyloid cardiomyopathy in patients with TTR V30M, per a new study.

Significant conduction abnormalities were more frequent than overt #AmyloidCardiomyopathy (CM) in patients with the #V30M mutation in the #Transthyretin (TTR) gene.

Learn more: https://bit.ly/4aQdXeP

#RareDisease #ATTRCM #TTRGene #MedSky

Six-Minute Walk Distance May Be Associated With Disease Severity in ATTR-CM A recent study shows physical performance is “remarkably compromised” in patients with ATTR-CM, as measured by the 6-minute walk test.

Physical performance is “remarkably compromised” in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), as measured by the 6-minute walk test. Study in BMC Cardiovascular Disorders.

Read more: https://bit.ly/4aAfJAM

#RareDisease #Cardiology #PhysicalPerformance #MedSky

Study Identifies Potential New Marker of ATTR-CM Increased mechanical dispersion may serve as a marker of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Increased mechanical dispersion is associated with advanced stages of transthyretin-mediated amyloid cardiomyopathy (#ATTRCM) and mortality, according to a new study published in Scientific Reports.

Read here: https://bit.ly/3MdhvxH

#RareDisease #MedSky

Happy HallowThankMas! 🎃 🦃 🎄

ATTR-CM Contributor Faye Adams is celebrating the season a little differently this year — by creating moments whenever she can, not just when the calendar says it’s time.

✨Read more here: https://bit.ly/47ZFb10

#RareDisease #ATTRCM #RareVoices #MedSky

NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance - PharmaTimes First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

#AlnylamUK #NICE #vutrisiran #Amvuttra #ATTRCM #NICEfinaldraftguidance #transthyretinamyloidosiswithcardiomyopathy #hereditaryATTR #stage1polyneuropathy #stage2polyneuropathy #NICEfinalguidance #HELIOSBstudy #cardiovascular #stiffheartdisease #AnnaTomlinson #CardiomyopathyUK
zurl.co/0yB9A

Tafamidis May Slow the Progression of ATTR-CM Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with ATTR-CM, per a recent study.

Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), whether or not they were treated with #Tafamidis. Study in Clinical Research in Cardiology.

Read more: https://bit.ly/4pun9d5

Structural Homogeneity a Hallmark of Cardiac, Mixed Phenotypes in ATTR ATTR fibrils caused by the T60A TTR gene variant have a single morphology but high compositional homogeneity, according to recent research.

Transthyretin amyloid (#ATTR) fibrils caused by the T60A TTR gene variant, which is associated with a mixed cardiac (#ATTRCM) and neuropathic (#ATTRPN), have a single morphology across patients and tissues. Study in Structure.

Read more: https://bit.ly/3M7nbsM

#RareDisease #Cardiology

AI Tool Successfully Distinguishes ATTR-CM From Other Diseases A new machine learning model performed better than the Mayo ATTR-CM score in discerning ATTR-CM from other heart conditions.

#AHA25: Researchers developed a machine learning model that outperforms the Mayo #ATTRCM score in differentiating the disease from other #CardiacConditions. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/441KpXt

#RareDisease #MedTech #Cardiology

Real-World Analysis Supports Efficacy of ATTR-CM Therapies A retrospective analysis of patient health records found that transthyretin stabilizers show clinical benefit in adults with ATTR-CM.

#AHA25: While #Transthyretin (TTR) stabilizers reduce the risk of cardiovascular events in patients with #ATTRCM in a real-world setting, data on #TTR gene silencers is more limited. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/485pntu

"We're entering an era where patients should expect not to die 𝘧𝘳𝘰𝘮 cardiac #amyloidosis but rather 𝘸𝘪𝘵𝘩 it.” — Dr. Michelle Kittleson

Early diagnosis + treatment are changing outcomes in #ATTRCM. Age-expected longevity may be w/in reach.
Read🔗 bit.ly/4qBtZid

Sponsored by Alnylam Pharmaceuticals

🆕 Concise Clinical Guidance addresses evaluation & management of #ATTRCM & provides updated strategies & best practices, taking into account expanding disease modifying therapies, #heartfailure therapies & potential future opportunities.

More: 🔗 https://bit.ly/4qBQvYd #JACC #Amyloidosis #CardioSky

New ACC Concise Clinical Guidance updates best practices for diagnosing and managing transthyretin amyloid #cardiomyopathy, highlighting disease-modifying and HF therapies plus future directions. https://bit.ly/49nYX7m

#JACC #Amyloidosis #ATTRCM #HeartFailure #CardioSky

Platelets Play a Key Role in MG Pathogenesis A new study supports the notion that activated platelets play a key role in the pathogenesis of myasthenia gravis (MG).

#LiverTransplantation and treatment with disease-modifying therapies significantly improve survival in patients with hereditary variant transthyretin amyloidosis, which can lead to cardiomyopathy (#ATTRCM) and polyneuropathy (#ATTRPN). @jinternmed.bsky.social

Read more: https://bit.ly/48j6jZt

Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://bit.ly/4gLv5DG

#HFSA2025 #JACC #CardioSky

New in #JACC: A cross-trial analysis of 3 cardiac amyloidosis #ATTRCM trials reveals time-dependent effects of modern disease-modifying therapies on mortality.

Get the details: www.jacc.org/doi/10.1016/...

#ATTRMeeting2025 #ATTR2025 #Amyloidosis #CardioSky

Cardiac MRI May Lead to Early Diagnosis in ATTR-CM Care The extracellular volume derived from cardiac MRI highly accurate in identifying patients with ATTR-CM with negative Tc-PyP scans.

The extracellular volume derived from cardiac #MRI is highly accurate in identifying patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM) who have negative technetium-99m-pyrophosphate (Tc-PyP) scans. @jaccjournals.bsky.social

Read more: https://bit.ly/47SHof0

#MedSky #RareSky

Read our latest issue: bit.ly/4jPdYRp

#Sunscreens #ATTRCM

Cardiovascular Weekly News – May 29th 2025 🫀 Cardiology Update: AI Heart Models, Stroke Mortality Drop, ATTR-CM Trial and More 🧬   From AI-powered diagnostics and stroke […] The post Cardiovascular Weekly News – May 29th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Cardiovascular Weekly News – May 29th 2025 #News #AIinhealthcare #ATTRCM #cardiology Comment below!

Cardiovascular Weekly News – May 29th 2025 🫀 Cardiology Update: AI Heart Models, Stroke Mortality Drop, ATTR-CM Trial and More 🧬   From AI-powered diagnostics and stroke […] The post Cardiovascular Weekly News – May 29th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Cardiovascular Weekly News – May 29th 2025 #News #AIinhealthcare #ATTRCM #cardiology Comment below!

Cardiovascular Weekly News – May 29th 2025 🫀 Cardiology Update: AI Heart Models, Stroke Mortality Drop, ATTR-CM Trial and More 🧬   From AI-powered diagnostics and stroke […] The post Cardiovascular Weekly News – May 29th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cardiovascular Weekly News – May 29th 2025 #News #AIinhealthcare #ATTRCM #cardiology Comment below!

11/11
How do patients with #ATTRCM die?

New insights from Kevin Alexander, MD and Masri Ahmad, MD #ATTRibuteCM at #HeartFailure2025

#CardioSky #MedSky #Cardiology

9/11
More from #ATTRibuteCM

In variant #ATTRCM, acoramidis led to a reduction in the composite of ACM/CVH, ACM and CVH.

These clinical benefits were accompanied by halting in the rise in NT-proBNP levels, suggesting underlying disease-modifying effects.

#CardioSky #MedSky #Cardiology

8/11
New data from #ATTRibuteCM presented at #HeartFailure2025

Intriguing analysis by Kevin Alexander, MD. High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM

#CardioSky #MedSky #Cardiology

3/11
Remarkable back-to-back! #HeartFailure2025 #LBCT by
Marianna Fontana.

Nex-z CRISPR gene editing based therapy in #ATTRCM. Main paper in @nejm.org www.nejm.org/doi/full/10....

New data by #ATTR type with consistent and durable TTR lowering

#CardioSky #MedSky #Cardiology

1/11
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:

#LBCT by Marianna Fontana

#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM

#CardioSky #MedSky #Cardiology

Acoramidis approved for heart condition treatment - PharmaTimes MHRA authorises drug for adults with rare heart muscle damage

#cardiology #Acoramidis #Beyonttra #Bayer #MHRA #cardiomyopathy #varianttransthyretinamyloidosis #wildtypetransthyretinamyloidosis #wildtypeATTRCM #ATTRCM #EMA #transthyretin #TTR #amyloiddeposits #Acoramidishydrochloride #TTRprotein #accesstomedicines
pharmatimes.com/news/acorami...

Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine Abstract. Development of specific therapies addressing the underlying diseases’ mechanisms constitutes the basis of precision medicine. Transthyretin cardi

🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀

📖 Read the full article: doi.org/10.1093/eurh...

#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social